UroGen Pharma Ltd. Stock News

UroGen Pharma Ltd. ( URGN ) Q3 2025 Earnings Call November 6, 2025 10:00 AM EST Company Participants Vincent Perrone - Senior Director of Investor Relations Elizabeth Barrett - President, CEO & Director Mark Schoenberg - Chief Medical Officer David Lin - Chief Commercial Officer Christopher Degnan - Chief Financial Officer Conference Call Participants Tara Bancroft - TD Cowen, Research Division...

Reported three-month complete response rate of 77.8% from the Phase 3 UTOPIA trial of UGN-103, consistent with ENVISION results; FDA agreed to regulatory plan to submit an NDA based on data from the UTOPIA trial ZUSDURI received unique J-Code (J9282) in October 2025, effective January 1, 2026 ZUSDURI achieved net product revenue of $1.8 million in Q3 2025; October 2025 preliminary demand revenu...

PRINCETON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced robust preliminary results from its ongoing Phase 3 UTOPIA trial, demonstrating a 77.8% three-month complete response (CR) rate (95% CI, 68.3%, 85.5%) with UGN-103 (mi...

PRINCETON, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

UroGen Pharma is revisited after a previous Strong Buy rating, with UroGen having increased ~95% since then. The article reflects on UroGen's RTGel technology, which supports JELMYTO and ZUSDURI, its two FDA-approved products. JELMYTO has grown its revenues, but they are starting to taper off.

Conference Call and Webcast Scheduled for Thursday, November 6th, 2025, at 10:00 AM ET Conference Call and Webcast Scheduled for Thursday, November 6th, 2025, at 10:00 AM ET

PRINCETON, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

PRINCETON, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.